Catalog No.
RAD10803
Host species
Rabbit
Isotype
IgG
Clonality
Monoclonal
Target
B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD19, CD19, Anti-FMC63
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P15391
Applications
ELISA, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA2162
Characterization of novel CD19-specific VHHs isolated from a camelid immune library by phage display., PMID:38066569
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study., PMID:38066564
T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts., PMID:36875091
Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition., PMID:36435066
A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL., PMID:35981465
Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation., PMID:35222427
Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains., PMID:35117999
Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy., PMID:33432627
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line., PMID:33271901
Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy., PMID:33023981
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia., PMID:32894185
Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma., PMID:32435496
[Construction and in vitro verification of a new humanized anti-CD19 CAR-T cells with high affinity]., PMID:30032561
Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia., PMID:29633386
Fully human CD19-specific chimeric antigen receptors for T-cell therapy., PMID:28202953
Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials., PMID:23469246
Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma., PMID:9566763
For research use only. Not for human or drug use.
